Lucid Diagnostics Inc.

For the period ended Dec 31, 2025. Filed Mar 25, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 25, 2026

LUCD$0.40-4.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Changes in Stockholders’Equity (Deficit)

for the YEARS ENDED December 31, 2025 and 2024

· · · · · · · · · · · · · · · · · · Additional · · · · · · · · ·
· · Preferred Stock · · · Common Stock · · · Paid-In · · · Accumulated · · · · ·
· · Shares · · · Amount · · · Shares · · · Amount · · · Capital · · · Deficit · · · Total ·
Balance as of December 31, 2023	18,625	$18,625	42,329,864	$42	$129,763	$(150,741)	$(2,311)
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan	—	—	3,333	—	4	—	4
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan	—	—	—	—	4,183	—	4,183
Stock-based compensation - PAVmed Inc. 2014 Equity Plan	—	—	—	—	351	—	351
Vest - restricted stock awards	—	—	26,912	—	—	—	—
Conversions - Senior Secured Convertible Note	—	—	13,866,867	14	13,468	—	13,482
Purchase - Employee Stock Purchase Plan	—	—	647,940	1	446	—	447
Issuance - Series A-1 Preferred Stock	5,670	5,670	—	—	—	—	5,670
Exchange - Series A and Series A-1 Preferred Stock	(24,295)	(24,295)	—	—	—	(7,496)	(31,791)
Issuance through exchange - Series B and Series B-1 Preferred Stock	31,790	31,790	—	—	—	—	31,790
Issuance through sale- Series B and Series B-1 Preferred Stock	24,129	24,129	—	—	—	—	24,129
Conversions - Series B Preferred Stock	(1,500)	(1,500)	2,075,263	2	1,498	—	—
Issuance - Due To: PAVmed Inc. Settlement in Common Stock	—	—	3,331,771	3	4,672	—	4,675
Issue common stock - vendor service agreement	—	—	790,000	1	640	—	641
Transfer of intellectual property from PAVmed Inc.	—	—	—	—	(350)	—	(350)
Net loss	—	—	—	—	—	(45,529)	(45,529)
Balance as of December 31, 2024	54,419	$54,419	63,071,950	$63	$154,675	$(203,766)	$5,391
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan	—	—	14,530	—	17	—	17
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan	—	—	—	—	4,387	—	4,387
Stock-based compensation - PAVmed Inc. 2014 Equity Plan	—	—	—	—	104	—	104
Issuance - At-The-Market Facility, net of deferred financing charges	—	—	215,421	—	274	—	274
Purchase - Employee Stock Purchase Plan	—	—	355,459	—	272	—	272
Issuance - Interest payment paid in stock	—	—	226,626	1	256	—	257
Issuance - Registered Direct Offering, net of fees	—	—	13,939,330	14	14,921	—	14,935
Issuance - Confidentially Marketing Public Offering, net of fees	—	—	43,125,000	43	43,128	—	43,171
Issuance - Dividend on Series B and Series B-1 Preferred Stock	—	—	9,921,423	10	12,549	(12,559)	—
Conversions - Series B Preferred Stock	(145)	(145)	116,523	—	145	—	—
Issue common stock - vendor service agreement	—	—	112,500	—	138	—	138
Net loss	—	—	—	—	—	(58,010)	(58,010)
Balance as of December 31, 2025	54,274	$54,274	131,098,762	$131	$230,866	$(274,335)	$10,936

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.